Latest Business and People News
Updated employee announcements, business news, awards, and recognition in the industry today.
People News
CDISC announced long-time standards advocate, skilled instructor, and current European Liaison, Peter Van Reusel, as the organization’s Chief Standards Officer.
4G Clinical, a randomization and trial supply management provider, announced the appointment of Jan Pieter Kappelle as VP of Strategy along with Neta Bendelac who will also be joining the team.
TrialScope, a company focused in clinical trial transparency and compliance solutions, announced that it has promoted Francine Lane to Vice President of Global Transparency.
Optimapharm, a full-service CRO, has appointed new team members, Roy Ovel as Chief Commercial Officer and Charles Denis Maher as Vice President Business Development (Americas).
Paul Hegwood
Catalent Pharma Solutions, a global provider of delivery technologies and development solutions for drugs, biologics, and consumer health products, announced that it has appointed Paul Hegwood as President of the company’s Clinical Supply Services business.
Business News
CROMSOURCE, an international CRO, announced the formalization of an expanded Flexible Resourcing Solutions offering, delivered by the TalentSource Life Sciences Department, with a new logo.
4G Clinical, a randomization and trial supply management provider, announced the opening of their new Tokyo office to further boost global expansion.
Endpoint Clinical, a global interactive response technology company, has expanded their global footprint to support their local clients in Europe and Asia.
Optimapharm, a full-service CRO, has expanded its office network to New York, USA, and Budapest, Hungary.
Recognition
CRF Health Receives Award
CRF Health, a global provider of patient-centered eSource technology solutions for the life sciences industry, announced that the company has been recognized as 2018 New Entrant of the Year in Romania’s Regional IT & Outsourcing Industry Awards.
PAREXEL, a biopharmaceutical services provider, announced that the Company has received recognition for its service and expertise from several notable industry organizations. These recognitions include Forbes “America’s Best Management Consulting Firms”, the Silver Stevie® Award, and the CRO Quality Award.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
